Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 26, 2003
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Determine the effectiveness of induction with high-dose mitoxantrone and cytarabine in patients with chronic myelogenous leukemia (CML) in blast crisis.
* Determine the toxicity and activity of consolidation with high-dose cyclophosphamide and etoposide in these patients.
* Determine the toxicity and activity of maintenance with interferon alfa in these patients.
* Determine the efficacy and tolerability of this regimen in these patients.
* Assess minimal residual disease by cytogenetics, DNA gene rearrangement (Southern blotting), and polymerase chain reaction (PCR) in patie...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Diagnosis of chronic myelogenous leukemia in blast crisis
- • Bone marrow blasts at least 20% OR
- • Bone marrow blasts plus promyelocytes at least 50%
- • Ineligible for higher priority protocols
- PATIENT CHARACTERISTICS:
- Age:
- • 16 and over
- Performance status:
- • Not specified
- Hematopoietic:
- • Not specified
- Hepatic:
- • Bilirubin less than 2.0 mg/dL
- Renal:
- • Creatinine less than 2.0 mg/dL
- Cardiovascular:
- • LVEF greater than 50% by MUGA scan or echocardiogram
- Other:
- • HIV negative
- • Not pregnant
- • Fertile patients must use effective contraception
- PRIOR CONCURRENT THERAPY:
- • Biologic therapy
- • Not specified
- • Chemotherapy
- • Not specified
- • Endocrine therapy
- • Not specified
- • Radiotherapy
- • Not specified
- • Surgery
- • Not specified
- • Other
- • Prior therapy for blast crisis allowed
Trial Officials
Mark Adam Weiss, MD
Study Chair
Memorial Sloan Kettering Cancer Center
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials